BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38720314)

  • 1. Diagnostic leukapheresis reveals distinct phenotypes of NSCLC circulating tumor cells.
    Rieckmann LM; Spohn M; Ruff L; Agorku D; Becker L; Borchers A; Krause J; O'Reilly R; Hille J; Velthaus-Rusik JL; Beumer N; Günther A; Willnow L; Imbusch CD; Iglauer P; Simon R; Franzenburg S; Winter H; Thomas M; Bokemeyer C; Gagliani N; Krebs CF; Sprick M; Hardt O; Riethdorf S; Trumpp A; Stoecklein NH; Peine S; Rosenstiel P; Pantel K; Loges S; Janning M
    Mol Cancer; 2024 May; 23(1):93. PubMed ID: 38720314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leukapheresis increases circulating tumour cell yield in non-small cell lung cancer, counts related to tumour response and survival.
    Tamminga M; Andree KC; van den Bos H; Hiltermann TJN; Mentink A; Spierings DCJ; Lansdorp P; Timens W; Schuuring E; Terstappen LWMM; Groen HJM
    Br J Cancer; 2022 Feb; 126(3):409-418. PubMed ID: 34848855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generating human prostate cancer organoids from leukapheresis enriched circulating tumour cells.
    Mout L; van Dessel LF; Kraan J; de Jong AC; Neves RPL; Erkens-Schulze S; Beaufort CM; Sieuwerts AM; van Riet J; Woo TLC; de Wit R; Sleijfer S; Hamberg P; Sandberg Y; Te Boekhorst PAW; van de Werken HJG; Martens JWM; Stoecklein NH; van Weerden WM; Lolkema MP
    Eur J Cancer; 2021 Jun; 150():179-189. PubMed ID: 33932725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Powering single-cell genomics to unravel circulating tumour cell subpopulations in non-small cell lung cancer patients.
    Acheampong E; Morici M; Abed A; Bowyer S; Asante DB; Lin W; Millward M; Gray ES; Beasley AB
    J Cancer Res Clin Oncol; 2023 May; 149(5):1941-1950. PubMed ID: 35896898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroups.
    Lindsay CR; Faugeroux V; Michiels S; Pailler E; Facchinetti F; Ou D; Bluthgen MV; Pannet C; Ngo-Camus M; Bescher G; Caramella C; Billiot F; Remon J; Planchard D; Soria JC; Besse B; Farace F
    Ann Oncol; 2017 Jul; 28(7):1523-1531. PubMed ID: 28633480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic leukapheresis for CTC analysis in breast cancer patients: CTC frequency, clinical experiences and recommendations for standardized reporting.
    Fehm TN; Meier-Stiegen F; Driemel C; Jäger B; Reinhardt F; Naskou J; Franken A; Neubauer H; Neves RPL; van Dalum G; Ruckhäberle E; Niederacher D; Rox JM; Fischer JC; Stoecklein NH
    Cytometry A; 2018 Dec; 93(12):1213-1219. PubMed ID: 30551262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluid biopsy for circulating tumor cell identification in patients with early-and late-stage non-small cell lung cancer: a glimpse into lung cancer biology.
    Wendel M; Bazhenova L; Boshuizen R; Kolatkar A; Honnatti M; Cho EH; Marrinucci D; Sandhu A; Perricone A; Thistlethwaite P; Bethel K; Nieva J; Heuvel Mv; Kuhn P
    Phys Biol; 2012 Feb; 9(1):016005. PubMed ID: 22307026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mesenchymal circulating tumor cells (CTCs) and OCT4 mRNA expression in CTCs for prognosis prediction in patients with non-small-cell lung cancer.
    Li S; Chen Q; Li H; Wu Y; Feng J; Yan Y
    Clin Transl Oncol; 2017 Sep; 19(9):1147-1153. PubMed ID: 28374320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in
    Pailler E; Faugeroux V; Oulhen M; Mezquita L; Laporte M; Honoré A; Lecluse Y; Queffelec P; NgoCamus M; Nicotra C; Remon J; Lacroix L; Planchard D; Friboulet L; Besse B; Farace F
    Clin Cancer Res; 2019 Nov; 25(22):6671-6682. PubMed ID: 31439588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlations between circulating tumor cell phenotyping and 18F-fluorodeoxyglucose positron emission tomography uptake in non-small cell lung cancer.
    Bian J; Yan K; Liu N; Xu X
    J Cancer Res Clin Oncol; 2020 Oct; 146(10):2621-2630. PubMed ID: 32661602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensitive detection of viable circulating tumor cells using a novel conditionally telomerase-selective replicating adenovirus in non-small cell lung cancer patients.
    Togo S; Katagiri N; Namba Y; Tulafu M; Nagahama K; Kadoya K; Takamochi K; Oh S; Suzuki K; Sakurai F; Mizuguchi H; Urata Y; Takahashi K
    Oncotarget; 2017 May; 8(21):34884-34895. PubMed ID: 28432274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Label-Free Enrichment and Molecular Characterization of Viable Circulating Tumor Cells from Diagnostic Leukapheresis Products.
    Franken A; Driemel C; Behrens B; Meier-Stiegen F; Endris V; Stenzinger A; Niederacher D; Fischer JC; Stoecklein NH; Ruckhaeberle E; Fehm T; Neubauer H
    Clin Chem; 2019 Apr; 65(4):549-558. PubMed ID: 30737205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Classification of circulating tumor cells by epithelial-mesenchymal transition markers.
    Wu S; Liu S; Liu Z; Huang J; Pu X; Li J; Yang D; Deng H; Yang N; Xu J
    PLoS One; 2015; 10(4):e0123976. PubMed ID: 25909322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumourigenic non-small-cell lung cancer mesenchymal circulating tumour cells: a clinical case study.
    Morrow CJ; Trapani F; Metcalf RL; Bertolini G; Hodgkinson CL; Khandelwal G; Kelly P; Galvin M; Carter L; Simpson KL; Williamson S; Wirth C; Simms N; Frankliln L; Frese KK; Rothwell DG; Nonaka D; Miller CJ; Brady G; Blackhall FH; Dive C
    Ann Oncol; 2016 Jun; 27(6):1155-1160. PubMed ID: 27013395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hexokinase 2 discerns a novel circulating tumor cell population associated with poor prognosis in lung cancer patients.
    Yang L; Yan X; Chen J; Zhan Q; Hua Y; Xu S; Li Z; Wang Z; Dong Y; Zuo D; Xue M; Tang Y; Herschman HR; Lu S; Shi Q; Wei W
    Proc Natl Acad Sci U S A; 2021 Mar; 118(11):. PubMed ID: 33836566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epithelial-mesenchymal transition and GALC expression of circulating tumor cells indicate metastasis and poor prognosis in non-small cell lung cancer.
    Liu DG; Xue L; Li J; Yang Q; Peng JZ
    Cancer Biomark; 2018; 22(3):417-426. PubMed ID: 29758927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression profiling of single circulating tumor cells in ovarian cancer - Establishment of a multi-marker gene panel.
    Blassl C; Kuhlmann JD; Webers A; Wimberger P; Fehm T; Neubauer H
    Mol Oncol; 2016 Aug; 10(7):1030-42. PubMed ID: 27157930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epithelial circulating tumor cells with a heterogeneous phenotype are associated with metastasis in NSCLC.
    Zhang Y; Men Y; Wang J; Xing P; Zhao J; Li J; Xu D; Hui Z; Cui W
    J Cancer Res Clin Oncol; 2022 May; 148(5):1137-1146. PubMed ID: 34255149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating tumor cells as a response monitor in stage IV non-small cell lung cancer.
    Shishido SN; Carlsson A; Nieva J; Bethel K; Hicks JB; Bazhenova L; Kuhn P
    J Transl Med; 2019 Aug; 17(1):294. PubMed ID: 31462312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic Leukapheresis Enables Reliable Transcriptomic Profiling of Single Circulating Tumor Cells to Characterize Inter-Cellular Heterogeneity in Terms of Endocrine Resistance.
    Reinhardt F; Franken A; Meier-Stiegen F; Driemel C; Stoecklein NH; Fischer JC; Niederacher D; Ruckhaeberle E; Fehm T; Neubauer H
    Cancers (Basel); 2019 Jun; 11(7):. PubMed ID: 31261643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.